Diabetes Care, Vol 23, Issue 7 888-892, Copyright © 2000 by American Diabetes Association

ARTICLES

Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes

M Pahor, BM Psaty, MH Alderman, WB Applegate, JD Williamson and CD Furberg
Sticht Center on Aging, Department of Internal Medicine, Wake Forest University, Winston-Salem, North Carolina 27157, USA. mpahor@wfubmc.edu

OBJECTIVE: To assess whether ACE inhibitors are superior to alternative agents for the prevention of cardiovascular events in patients with hypertension and type 2 diabetes. RESEARCH DESIGN AND METHODS: This study is a review and meta-analysis of randomized controlled trials that included patients with type 2 diabetes and hypertension who were randomized to an ACE inhibitor or an alternative drug, were followed for > or =2 years, and had adjudicated cardiovascular events. RESULTS: A total of 4 trials were eligible. The Appropriate Blood Pressure Control in Diabetes (ABCD) trial (n = 470) compared enalapril with nisoldipine, the Captopril Prevention Project (CAPPP) (n = 572) compared captopril with diuretics or beta-blockers, the Fosinopril Versus Amlodipine Cardiovascular Events Trial (FACET) (n = 380) compared fosinopril with amlodipine, and the U.K. Prospective Diabetes Study (UKPDS) (n = 758) compared captopril with atenolol. The cumulative results of the first 3 trials showed a significant benefit of ACE inhibitors compared with alternative treatments on the outcomes of acute myocardial infarction (63% reduction, P < 0.001), cardiovascular events (51% reduction, P < 0.001), and all-cause mortality (62% reduction, P = 0.010). These findings were not observed in the UKPDS. The ACE inhibitors did not appear to be superior to other agents for the outcome of stroke in any of the trials. None of the findings were explained by differences in blood pressure control. CONCLUSIONS: Compared with the alternative agents tested, ACE inhibitors may provide a special advantage in addition to blood pressure control. The question of whether atenolol is equivalent to captopril remains open. Conclusive evidence on the comparative effects of antihypertensive treatments will come from large prospective randomized trials.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. R. Holman, S. K. Paul, M. A. Bethel, H. A. W. Neil, and D. R. Matthews Long-Term Follow-up after Tight Control of Blood Pressure in Type 2 Diabetes N. Engl. J. Med., October 9, 2008; 359(15): 1565 - 1576. [Abstract] [Full Text] [PDF]

				E. L. Air and B. M. Kissela Diabetes, the Metabolic Syndrome, and Ischemic Stroke: Epidemiology and possible mechanisms Diabetes Care, December 1, 2007; 30(12): 3131 - 3140. [Full Text] [PDF]

				A. Whaley-Connell, B. S. Pavey, K. Chaudhary, G. Saab, and J. R. Sowers Review: Renin-angiotensin-aldosterone system intervention in the cardiometabolic syndrome and cardio-renal protection Therapeutic Advances in Cardiovascular Disease, October 1, 2007; 1(1): 27 - 35. [Abstract] [PDF]

				M. H. Strauss and A. S. Hall Angiotensin Receptor Blockers May Increase Risk of Myocardial Infarction: Unraveling the ARB-MI Paradox Circulation, August 22, 2006; 114(8): 838 - 854. [Full Text] [PDF]

				N. R. Burrows, A. S. Narva, L. S. Geiss, M. M. Engelgau, and K. J. Acton End-Stage Renal Disease due to Diabetes Among Southwestern American Indians, 1990-2001 Diabetes Care, May 1, 2005; 28(5): 1041 - 1044. [Abstract] [Full Text] [PDF]

				M. J. Katovich, J. L. Grobe, M. Huentelman, and M. K. Raizada Angiotensin-converting enzyme 2 as a novel target for gene therapy for hypertension Exp Physiol, May 1, 2005; 90(3): 299 - 305. [Abstract] [Full Text] [PDF]

				B. J Epstein and J. G Gums Angiotensin Receptor Blockers versus ACE Inhibitors: Prevention of Death and Myocardial Infarction in High-Risk Populations Ann. Pharmacother., March 1, 2005; 39(3): 470 - 480. [Abstract] [Full Text] [PDF]

				K. M. Field, J. L. Pepin, and M. D. Mehta Knowing When to Play the Ace: The Use and Under Use of Ace Inhibitors in Primary Practice Journal of Pharmacy Practice, June 1, 2004; 17(3): 197 - 210. [Abstract] [PDF]

				J. A. Joles and H. A. Koomans Causes and Consequences of Increased Sympathetic Activity in Renal Disease Hypertension, April 1, 2004; 43(4): 699 - 706. [Abstract] [Full Text] [PDF]

				T. Berl Angiotensin-Converting Enzyme Inhibitors versus AT1 Receptor Antagonist in Cardiovascular and Renal Protection: The case for AT1 Receptor Antagonist J. Am. Soc. Nephrol., January 1, 2004; 15(90010): S71 - 76. [Abstract] [Full Text]

				P. Sleight PPOGRESS beyond HOPE and LIFE: The ONTARGET trial programme Eur. Heart J. Suppl., August 1, 2003; 5(suppl_F): F40 - F47. [Abstract] [PDF]

				B. M. Psaty, T. Lumley, C. D. Furberg, G. Schellenbaum, M. Pahor, M. H. Alderman, and N. S. Weiss Health Outcomes Associated With Various Antihypertensive Therapies Used as First-Line Agents: A Network Meta-analysis JAMA, May 21, 2003; 289(19): 2534 - 2544. [Abstract] [Full Text] [PDF]

				T. Berl, L. G. Hunsicker, J. B. Lewis, M. A. Pfeffer, J. G. Porush, J.-L. Rouleau, P. L. Drury, E. Esmatjes, D. Hricik, C. R. Parikh, et al. Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy Ann Intern Med, April 1, 2003; 138(7): 542 - 549. [Abstract] [Full Text] [PDF]

				V. Snow, K. B. Weiss, C. Mottur-Pilson, and for the Clinical Efficacy Assessment Subcommittee The Evidence Base for Tight Blood Pressure Control in the Management of Type 2 Diabetes Mellitus Ann Intern Med, April 1, 2003; 138(7): 587 - 592. [Abstract] [Full Text] [PDF]

				R. Harris, K. Donahue, S. S. Rathore, P. Frame, S. H. Woolf, and K. N. Lohr Screening Adults for Type 2 Diabetes: A Review of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, February 4, 2003; 138(3): 215 - 229. [Abstract] [Full Text] [PDF]

				M. Pahor, L. V. Franse, S. R. Deitcher, W. C. Cushman, K. C. Johnson, R. I. Shorr, K. Kottke-Marchant, R. P. Tracy, G. W. Somes, and W. B. Applegate Fosinopril Versus Amlodipine Comparative Treatments Study: A Randomized Trial to Assess Effects on Plasminogen Activator Inhibitor-1 Circulation, January 29, 2002; 105(4): 457 - 461. [Abstract] [Full Text] [PDF]

				C. D. Furberg, B. M. Psaty, M. Pahor, and M. H. Alderman Clinical Implications of Recent Findings from the Antihypertensive and Lipid-Lowering Treatment To Prevent Heart Attack Trial (ALLHAT) and Other Studies of Hypertension Ann Intern Med, December 18, 2001; 135(12): 1074 - 1078. [Abstract] [Full Text] [PDF]

				N. M. Kaplan Management of Hypertension in Patients with Type 2 Diabetes Mellitus: Guidelines Based on Current Evidence Ann Intern Med, December 18, 2001; 135(12): 1079 - 1083. [Abstract] [Full Text] [PDF]

				V. M Montori Review: intensive blood pressure control and drugs reduce morbidity and mortality in hypertension and diabetes mellitus Evid. Based Med., March 1, 2001; 6(2): 44 - 44. [Full Text]

				E. Barrett-Connor and D. L Wingard ""Normal"" blood glucose and coronary risk BMJ, January 6, 2001; 322(7277): 5 - 6. [Full Text] [PDF]

				End-Stage Renal Disease Attributed to Diabetes Among American Indians/Alaska Natives With Diabetes--United States, 1990-1996 JAMA, January 3, 2001; 285(1): 37 - 38. [Full Text] [PDF]

				M. Pahor, B. M. Psaty, M. H. Alderman, and C. D. Furberg Meta-analysis of Hypertension Trials in Diabetic Patients: Response to Parving and Rossing Diabetes Care, January 1, 2001; 24(1): 178 - 180. [Full Text]

				H.-H. Parving and P. Rossing Therapeutic Benefits of ACE Inhibitors and Other Antihypertensive Drugs in Patients With Type 2 Diabetes Diabetes Care, January 1, 2001; 24(1): 177-a - 178. [Full Text]